Review



on-targetplus smartpool sirna targeting human nsd3  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Thermo Fisher on-targetplus smartpool sirna targeting human nsd3
    Identification of cancer amplified genes with high copy number versus expression correlation.
    On Targetplus Smartpool Sirna Targeting Human Nsd3, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/on-targetplus+smartpool+sirna+targeting+human+nsd3/shrnas/pmc04038530-109-10-12
    Average 90 stars, based on 1 article reviews
    on-targetplus smartpool sirna targeting human nsd3 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets"

    Article Title: Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0098293

    Identification of cancer amplified genes with high copy number versus expression correlation.
    Figure Legend Snippet: Identification of cancer amplified genes with high copy number versus expression correlation.

    Techniques Used: Amplification, Expressing, Ubiquitin Proteomics

    (A) Copy number (x-axis) and mRNA expression (y-axis) for NSD3 and SETD1 in breast cancers and melanomas, respectively. Correlation coefficient for copy number and mRNA expression are listed in the top right (r value). (B) BRD4 and YEATS4 shRNA activity in a panel of cancer cell lines (Project Achilles). shRNA score denotes the log2 based decrease in the representative shRNA compared to pooled shRNA in cancer cell lines after several rounds of proliferation post-shRNA . Yellow bars indicate cell lines with BRD4 or YEATS4 copy number >4 and black bars indicate cell lines with BRD4 or YEATS4 copy number <4. (C) Frequency of amplification (red bar), mutation (green bar), and deletion (blue bar) for NSD3 , SETDB1 , YEATS4 , and BRD4 in various cancers. The percentages shown reflect the overall rate of gene amplification, mutation and/or deletion in each cancer type. Vertical aligned bars reflect samples from the same patient. (D) Relative NSD3 protein level (y-axis, normalized to b-actin protein levels) compared with NSD3 copy number (x-axis) in SW48, H1581, SW837, and H1703 cells. (E) Relative proliferation (y-axis) and (F) relative apoptosis levels of cancer cell lines H1581, H1703, SW48, and SW837 cells 3 days after transfection with NSD3 siRNA, as measured by Cell Titer Glo and Caspase Glo assays, respectively. (G) Cell cycle profile of H1703 cells 24 or 48 hours after transfection with NSD3 siRNA compared to non-transfected controls. (H) Relative changes of cells in apoptosis, G1 or G2 phases (y-axis) in cell lines 48 hours-post NSD3 siRNA transfection compared to uninfected controls.
    Figure Legend Snippet: (A) Copy number (x-axis) and mRNA expression (y-axis) for NSD3 and SETD1 in breast cancers and melanomas, respectively. Correlation coefficient for copy number and mRNA expression are listed in the top right (r value). (B) BRD4 and YEATS4 shRNA activity in a panel of cancer cell lines (Project Achilles). shRNA score denotes the log2 based decrease in the representative shRNA compared to pooled shRNA in cancer cell lines after several rounds of proliferation post-shRNA . Yellow bars indicate cell lines with BRD4 or YEATS4 copy number >4 and black bars indicate cell lines with BRD4 or YEATS4 copy number <4. (C) Frequency of amplification (red bar), mutation (green bar), and deletion (blue bar) for NSD3 , SETDB1 , YEATS4 , and BRD4 in various cancers. The percentages shown reflect the overall rate of gene amplification, mutation and/or deletion in each cancer type. Vertical aligned bars reflect samples from the same patient. (D) Relative NSD3 protein level (y-axis, normalized to b-actin protein levels) compared with NSD3 copy number (x-axis) in SW48, H1581, SW837, and H1703 cells. (E) Relative proliferation (y-axis) and (F) relative apoptosis levels of cancer cell lines H1581, H1703, SW48, and SW837 cells 3 days after transfection with NSD3 siRNA, as measured by Cell Titer Glo and Caspase Glo assays, respectively. (G) Cell cycle profile of H1703 cells 24 or 48 hours after transfection with NSD3 siRNA compared to non-transfected controls. (H) Relative changes of cells in apoptosis, G1 or G2 phases (y-axis) in cell lines 48 hours-post NSD3 siRNA transfection compared to uninfected controls.

    Techniques Used: Expressing, shRNA, Activity Assay, Amplification, Mutagenesis, Transfection

    Related Articles

    Knockdown:

    Article Title: Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets
    Article Snippet: .. For NSD3 knockdown studies, we used On-Targetplus SMARTpool siRNA targeting human Nsd3 (Thermo Scientific). ..



    Similar Products

    on-targetplus smartpool sirna targeting human nsd3  (Thermo Fisher)
    90
    Thermo Fisher on-targetplus smartpool sirna targeting human nsd3
    Identification of cancer amplified genes with high copy number versus expression correlation.
    On Targetplus Smartpool Sirna Targeting Human Nsd3, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/on-targetplus+smartpool+sirna+targeting+human+nsd3/shrnas/pmc04038530-109-10-12
    Average 90 stars, based on 1 article reviews
    on-targetplus smartpool sirna targeting human nsd3 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Identification of cancer amplified genes with high copy number versus expression correlation.

    Journal: PLoS ONE

    Article Title: Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets

    doi: 10.1371/journal.pone.0098293

    Figure Lengend Snippet: Identification of cancer amplified genes with high copy number versus expression correlation.

    Article Snippet: For NSD3 knockdown studies, we used On-Targetplus SMARTpool siRNA targeting human Nsd3 (Thermo Scientific).

    Techniques: Amplification, Expressing, Ubiquitin Proteomics

    (A) Copy number (x-axis) and mRNA expression (y-axis) for NSD3 and SETD1 in breast cancers and melanomas, respectively. Correlation coefficient for copy number and mRNA expression are listed in the top right (r value). (B) BRD4 and YEATS4 shRNA activity in a panel of cancer cell lines (Project Achilles). shRNA score denotes the log2 based decrease in the representative shRNA compared to pooled shRNA in cancer cell lines after several rounds of proliferation post-shRNA . Yellow bars indicate cell lines with BRD4 or YEATS4 copy number >4 and black bars indicate cell lines with BRD4 or YEATS4 copy number <4. (C) Frequency of amplification (red bar), mutation (green bar), and deletion (blue bar) for NSD3 , SETDB1 , YEATS4 , and BRD4 in various cancers. The percentages shown reflect the overall rate of gene amplification, mutation and/or deletion in each cancer type. Vertical aligned bars reflect samples from the same patient. (D) Relative NSD3 protein level (y-axis, normalized to b-actin protein levels) compared with NSD3 copy number (x-axis) in SW48, H1581, SW837, and H1703 cells. (E) Relative proliferation (y-axis) and (F) relative apoptosis levels of cancer cell lines H1581, H1703, SW48, and SW837 cells 3 days after transfection with NSD3 siRNA, as measured by Cell Titer Glo and Caspase Glo assays, respectively. (G) Cell cycle profile of H1703 cells 24 or 48 hours after transfection with NSD3 siRNA compared to non-transfected controls. (H) Relative changes of cells in apoptosis, G1 or G2 phases (y-axis) in cell lines 48 hours-post NSD3 siRNA transfection compared to uninfected controls.

    Journal: PLoS ONE

    Article Title: Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets

    doi: 10.1371/journal.pone.0098293

    Figure Lengend Snippet: (A) Copy number (x-axis) and mRNA expression (y-axis) for NSD3 and SETD1 in breast cancers and melanomas, respectively. Correlation coefficient for copy number and mRNA expression are listed in the top right (r value). (B) BRD4 and YEATS4 shRNA activity in a panel of cancer cell lines (Project Achilles). shRNA score denotes the log2 based decrease in the representative shRNA compared to pooled shRNA in cancer cell lines after several rounds of proliferation post-shRNA . Yellow bars indicate cell lines with BRD4 or YEATS4 copy number >4 and black bars indicate cell lines with BRD4 or YEATS4 copy number <4. (C) Frequency of amplification (red bar), mutation (green bar), and deletion (blue bar) for NSD3 , SETDB1 , YEATS4 , and BRD4 in various cancers. The percentages shown reflect the overall rate of gene amplification, mutation and/or deletion in each cancer type. Vertical aligned bars reflect samples from the same patient. (D) Relative NSD3 protein level (y-axis, normalized to b-actin protein levels) compared with NSD3 copy number (x-axis) in SW48, H1581, SW837, and H1703 cells. (E) Relative proliferation (y-axis) and (F) relative apoptosis levels of cancer cell lines H1581, H1703, SW48, and SW837 cells 3 days after transfection with NSD3 siRNA, as measured by Cell Titer Glo and Caspase Glo assays, respectively. (G) Cell cycle profile of H1703 cells 24 or 48 hours after transfection with NSD3 siRNA compared to non-transfected controls. (H) Relative changes of cells in apoptosis, G1 or G2 phases (y-axis) in cell lines 48 hours-post NSD3 siRNA transfection compared to uninfected controls.

    Article Snippet: For NSD3 knockdown studies, we used On-Targetplus SMARTpool siRNA targeting human Nsd3 (Thermo Scientific).

    Techniques: Expressing, shRNA, Activity Assay, Amplification, Mutagenesis, Transfection